The effect of metformin on insulin resistance and exercise parameters in patients with heart failure

Abstract

AimsChronic heart failure (CHF) is an insulin-resistant state. The degree of insulin resistance (IR) correlates with disease severity and is associated with reduced exercise capacity. In this proof of concept study, we have examined the effect of metformin on IR and exercise capacity in non-diabetic CHF patients identified to have IR. Methods and resultsIn a double-blind, placebo-controlled study, 62 non-diabetic IR CHF patients (mean age, 65.2 + 8.0 years; male, 90%; left ventricular ejection fraction, 32.6 + 8.3%; New York Heart Association class I/II/III/IV, 11/45/6/0) were randomized to receive either 4 months of metformin (n ¼ 39, 2 g/day) or matching placebo (n ¼ 23). IR was defined by a fasting insulin resistance index (FIRI) ≥2.7. Cardiopulmonary exercise testing and FIRI were assessed at baseline and after 4 months of intervention. Compared with placebo, metformin decreased FIRI (from 5.8 + 3.8 to 4.0 + 2.5, P , 0.001) and resulted in a weight loss of 1.9 kg (P , 0.001). The primary endpoint of the study, peak oxygen uptake (VO 2 ), did not differ between treatment groups. However, metformin improved the secondary endpoint of the slope of the ratio of minute ventilation to carbon dioxide production (VE/VCO 2 slope), from 32.9 + 15.9 to 28.1 + 8.8 (P ¼ 0.034). In the metformin-treated group, FIRI was significantly related to the reduction of the VE/ VCO 2 slope (R ¼ 0.41, P ¼ 0.036). ConclusionMetformin treatment significantly improved IR but had no effect on peak VO 2 , the primary endpoint of our study. However, metformin treatment did result in a significant improvement in VE/VCO 2 slope.

“Heart failure, whole-body insulin resistance and myocardial insulin resistance: An intriguing puzzle”

“…However, in the GIPS (Glycometabolic Intervention as Adjunct to Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction) III 24 in patients without DM presenting with acute coronary syndrome, the use of metformin compared with placebo did not result in improved systolic dysfunction. In addition, the TAYSIDE trial (Metformin in Insulin Resistant LV Dysfunction, a Double-blind, Placebo-controlled Trial), 25 designed to determine whether metformin can improve insulin sensitivity in patients with HF and whole-body IR, failed to demonstrate the improvement of exercise capacity and left ventricular ejection fraction in comparison with placebo, despite IR improvement.…”

Chikusetsu saponin IVa regulates glucose uptake and fatty acid oxidation: implications in antihyperglycemic and hypolipidemic effects

“…Cells were incubated in the presence or in the absence of 1 μg/ml CHS for 15 min and then washed two times with washing buffer (20 mM HEPES (pH 7.4), 140 mM NaCl, 5 mM KCl, 2.5 mM MgSO4 and 1 mM CaCl2). Cells were then incubated in transport solution (the buffer containing 0.5 mCi 2-deoxy- [1][2][3] H]-glucose and 10 μm 2-deoxyglucose) for 10 min. Non-specific uptake was determined with incubating the cells in the presence or in the absence of 5 mM cytochalasin B.…”

“…[1] Regulatory mechanisms of physical exercise and two major classes of anti-diabetic drugs (biguanides and thiazolidinediones) were much reported. [2,3] Novel besides, a good practice and bright future had been shown in the therapy of diabetes and its complications by natural products. [4] Exciting developments in type 2 diabetes therapy had shown that adenosine monophosphate (AMP)-activated protein kinase (AMPK) was one of the probable target of major anti-diabetic drugs (metformin and thiazolidinediones), and of insulinsensitizing adipokines (e.g.…”

Metformin Therapy and Circulating NT-proBNP Levels: The CAMERA Trial

“…Previous small studies suggested metformin therapy may improve left ventricular function and other functional tests of status (2,3). By contrast, a recent trial of 500 patients showed no effect on left ventricular function over 4 months following myocardial infarction (4).…”